Ely S - Search Results

1

Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.

Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. Mark TM, et al. Among authors: ely s. Leuk Lymphoma. 2014 Dec;55(12):2842-9. doi: 10.3109/10428194.2014.896005. Epub 2014 Mar 25. Leuk Lymphoma. 2014. PMID: 24576165 Clinical Trial.

2

CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells.

Tourigny MR, Ursini-Siegel J, Lee H, Toellner KM, Cunningham AF, Franklin DS, Ely S, Chen M, Qin XF, Xiong Y, MacLennan IC, Chen-Kiang S. Tourigny MR, et al. Among authors: ely s. Immunity. 2002 Aug;17(2):179-89. doi: 10.1016/s1074-7613(02)00364-3. Immunity. 2002. PMID: 12196289 Free article.

3

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM. Leonard JP, et al. Among authors: ely s. J Clin Oncol. 2003 Aug 15;21(16):3051-9. doi: 10.1200/JCO.2003.01.082. Epub 2003 Jul 1. J Clin Oncol. 2003. PMID: 12837807 Clinical Trial.

4

Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1.

Huang X, Di Liberto M, Cunningham AF, Kang L, Cheng S, Ely S, Liou HC, Maclennan IC, Chen-Kiang S. Huang X, et al. Among authors: ely s. Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17789-94. doi: 10.1073/pnas.0406111101. Epub 2004 Dec 10. Proc Natl Acad Sci U S A. 2004. PMID: 15591344 Free PMC article.

5

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.

Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ. Jungbluth AA, et al. Among authors: ely s. Blood. 2005 Jul 1;106(1):167-74. doi: 10.1182/blood-2004-12-4931. Epub 2005 Mar 10. Blood. 2005. PMID: 15761016 Free article.

6

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S. Ely S, et al. Cancer Res. 2005 Dec 15;65(24):11345-53. doi: 10.1158/0008-5472.CAN-05-2159. Cancer Res. 2005. PMID: 16357141

7

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. Baughn LB, et al. Among authors: ely s. Cancer Res. 2006 Aug 1;66(15):7661-7. doi: 10.1158/0008-5472.CAN-06-1098. Cancer Res. 2006. PMID: 16885367

8

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. Niesvizky R, et al. Among authors: ely s. Br J Haematol. 2007 Sep;138(5):640-3. doi: 10.1111/j.1365-2141.2007.06698.x. Br J Haematol. 2007. PMID: 17686058 Free article. Clinical Trial.

9

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M. Niesvizky R, et al. Among authors: ely s. Blood. 2008 Feb 1;111(3):1101-9. doi: 10.1182/blood-2007-05-090258. Epub 2007 Nov 7. Blood. 2008. PMID: 17989313 Free article. Clinical Trial.

10

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Martin P, et al. Among authors: ely s. Ann Oncol. 2008 Jul;19(7):1327-1330. doi: 10.1093/annonc/mdn045. Epub 2008 Mar 17. Ann Oncol. 2008. PMID: 18349031 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

359 results

Search Page